Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2020

01-12-2020 | Multiple Myeloma | Review

XPO1-dependent nuclear export as a target for cancer therapy

Authors: Nancy G. Azizian, Yulin Li

Published in: Journal of Hematology & Oncology | Issue 1/2020

Login to get access

Abstract

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.
Literature
1.
Kimura M, Imamoto N. Biological significance of the importin-beta family-dependent nucleocytoplasmic transport pathways. Traffic. 2014;15(7):727–48.PubMedCrossRef
2.
3.
Adachi Y, Yanagida M. Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein preferentially localized in the nucleus and its periphery. J Cell Biol. 1989;108(4):1195–207.PubMedCrossRef
4.
Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell. 1997;90(6):1041–50.PubMedCrossRef
5.
Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 2007;17(4):193–201.PubMedCrossRef
6.
7.
8.
Fu SC, Huang HC, Horton P, Juan HF. ValidNESs: a database of validated leucine-rich nuclear export signals. Nucleic Acids Res. 2013;41(Database issue):D338–43.PubMedCrossRef
9.
Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 2016;538(7623):114–7.PubMedPubMedCentralCrossRef
10.
Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85.PubMedPubMedCentralCrossRef
11.
Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A. 1998;95(13):7457–62.PubMedPubMedCentralCrossRef
12.
Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016;7(13):16581–92.PubMedPubMedCentralCrossRef
13.
Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, et al. Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS One. 2015;10(9):e0137210.PubMedPubMedCentralCrossRef
14.
Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2014;74(3):487–95.PubMedPubMedCentralCrossRef
15.
Kirli K, Karaca S, Dehne HJ, Samwer M, Pan KT, Lenz C, et al. A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning. Elife. 2015;4.
16.
Thomas F, Kutay U. Biogenesis and nuclear export of ribosomal subunits in higher eukaryotes depend on the CRM1 export pathway. J Cell Sci. 2003;116(Pt 12):2409–19.PubMedCrossRef
17.
Shaw DJ, Eggleton P, Young PJ. Joining the dots: production, processing and targeting of U snRNP to nuclear bodies. Biochim Biophys Acta. 2008;1783(11):2137–44.PubMedCrossRef
18.
Martinez I, Hayes KE, Barr JA, Harold AD, Xie M, Bukhari SIA, et al. An Exportin-1-dependent microRNA biogenesis pathway during human cell quiescence. Proc Natl Acad Sci U S A. 2017;114(25):E4961–70.PubMedPubMedCentralCrossRef
19.
Castanotto D, Lingeman R, Riggs AD, Rossi JJ. CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A. 2009;106(51):21655–9.PubMedPubMedCentralCrossRef
20.
Bussing I, Yang JS, Lai EC, Grosshans H. The nuclear export receptor XPO-1 supports primary miRNA processing in C. elegans and drosophila. EMBO J. 2010;29(11):1830–9.PubMedPubMedCentralCrossRef
21.
Muqbil I, Bao B, Abou-Samra AB, Mohammad RM, Azmi AS. Nuclear export mediated regulation of microRNAs: potential target for drug intervention. Curr Drug Targets. 2013;14(10):1094–100.PubMedPubMedCentralCrossRef
22.
Wu J, Bao A, Chatterjee K, Wan Y, Hopper AK. Genome-wide screen uncovers novel pathways for tRNA processing and nuclear-cytoplasmic dynamics. Genes Dev. 2015;29(24):2633–44.PubMedPubMedCentral
23.
Wickramasinghe VO, Laskey RA. Control of mammalian gene expression by selective mRNA export. Nat Rev Mol Cell Biol. 2015;16(7):431–42.PubMedCrossRef
24.
Okamura M, Inose H, Masuda S. RNA export through the NPC in eukaryotes. Genes (Basel). 2015;6(1):124–49.CrossRef
25.
Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden KLB. A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery. RNA. 2017;23(6):927–37.PubMedPubMedCentralCrossRef
26.
Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. 2016;127(7):858–68.PubMedPubMedCentralCrossRef
27.
Topisirovic I, Siddiqui N, Lapointe VL, Trost M, Thibault P, Bangeranye C, et al. Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP. EMBO J. 2009;28(8):1087–98.PubMedPubMedCentralCrossRef
28.
Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol. 2006;175(3):415–26.PubMedPubMedCentralCrossRef
29.
Wozniak R, Burke B, Doye V. Nuclear transport and the mitotic apparatus: an evolving relationship. Cell Mol Life Sci. 2010;67(13):2215–30.PubMedCrossRef
30.
31.
Arnaoutov A, Azuma Y, Ribbeck K, Joseph J, Boyarchuk Y, Karpova T, et al. Crm1 is a mitotic effector of ran-GTP in somatic cells. Nat Cell Biol. 2005;7(6):626–32.PubMedCrossRef
32.
Torosantucci L, De Luca M, Guarguaglini G, Lavia P, Degrassi F. Localized RanGTP accumulation promotes microtubule nucleation at kinetochores in somatic mammalian cells. Mol Biol Cell. 2008;19(5):1873–82.PubMedPubMedCentralCrossRef
33.
Liu Q, Jiang Q, Zhang C. A fraction of Crm1 locates at centrosomes by its CRIME domain and regulates the centrosomal localization of pericentrin. Biochem Biophys Res Commun. 2009;384(3):383–8.PubMedCrossRef
34.
Saulino DM, Younes PS, Bailey JM, Younes M. CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity. Oncotarget. 2018;9(30):21289–95.PubMedPubMedCentralCrossRef
35.
Chen Y, Camacho SC, Silvers TR, Razak AR, Gabrail NY, Gerecitano JF, et al. Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin Cancer Res. 2017;23(6):1552–63.PubMedCrossRef
36.
Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009;65(1):153–9 discussion 159-160.PubMedCrossRef
37.
Gupta A, Saltarski JM, White MA, Scaglioni PP, Gerber DE. Therapeutic targeting of nuclear export inhibition in lung cancer. J Thorac Oncol. 2017;12(9):1446–50.PubMedPubMedCentralCrossRef
38.
Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, et al. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep. 2018;8(1):12248.PubMedPubMedCentralCrossRef
39.
Gravina GL, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L, et al. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models. BMC Cancer. 2015;15:941.PubMedPubMedCentralCrossRef
40.
Aladhraei M, Kassem Al-Thobhani A, Poungvarin N, Suwannalert P. Association of XPO1 overexpression with NF-kappaB and Ki67 in colorectal cancer. Asian Pac J Cancer Prev. 2019;20(12):3747–54.PubMedPubMedCentralCrossRef
41.
Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA, et al. Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. Leukemia. 2017;31(7):1625–9.PubMedCrossRef
42.
Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K, et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell. 2012;45(2):222–32.PubMedPubMedCentralCrossRef
43.
Muralidharan R, Mehta M, Ahmed R, Roy S, Xu L, Aube J, et al. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 2017;7(1):9694.PubMedPubMedCentralCrossRef
44.
Jiang JH, Gao Q, Ke AW, Yu Y, Shi GM, Fan J, et al. Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma. Oncol Lett. 2014;7(3):641–6.PubMedPubMedCentralCrossRef
45.
Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, et al. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res. 2012;18(2):380–91.PubMedCrossRef
46.
47.
Yuen HF, Chan KK, Platt-Higgins A, el Dakir H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, et al. Ran GTPase promotes cancer progression via met recepto-rmediated downstream signaling. Oncotarget. 2016;7(46):75854–64.PubMedPubMedCentralCrossRef
48.
Consortium APG. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818–31.CrossRef
49.
Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov. 2019;9(10):1452–67.PubMedPubMedCentralCrossRef
50.
51.
Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101–5.PubMedPubMedCentralCrossRef
52.
Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341–6.PubMedCrossRef
53.
Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016;7:11987.PubMedPubMedCentralCrossRef
54.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–94 e415.PubMedPubMedCentralCrossRef
55.
Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res. 2012;72(3):757–68.PubMedCrossRef
56.
57.
Hamamoto T, Uozumi T, Beppu T. Leptomycins a and B, new antifungal antibiotics. III. Mode of action of leptomycin B on Schizosaccharomyces pombe. J Antibiot (Tokyo). 1985;38(11):1573–80.CrossRef
58.
Hamamoto T, Gunji S, Tsuji H, Beppu T. Leptomycins a and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo). 1983;36(6):639–45.CrossRef
59.
Komiyama K, Okada K, Tomisaka S, Umezawa I, Hamamoto T, Beppu T. Antitumor activity of leptomycin B. J Antibiot (Tokyo). 1985;38(3):427–9.CrossRef
60.
61.
Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J Biol Chem. 1994;269(9):6320–4.PubMed
62.
Koster M, Lykke-Andersen S, Elnakady YA, Gerth K, Washausen P, Hofle G, et al. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res. 2003;286(2):321–31.PubMedCrossRef
63.
Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013;110(4):1303–8.PubMedPubMedCentralCrossRef
64.
Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009;69(2):510–7.PubMedPubMedCentralCrossRef
65.
Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118(14):3922–31.PubMedCrossRef
66.
Saito N, Sakakibara K, Sato T, Friedman JM, Kufe DW, VonHoff DD, et al. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway. Mol Cancer Ther. 2014;13(12):3013–23.PubMedCrossRef
67.
Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, et al. A synthetic HIV-1 rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A. 2002;99(22):14440–5.PubMedPubMedCentralCrossRef
68.
Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D. Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther. 2016;1:16010.PubMedPubMedCentralCrossRef
69.
Camus V, Miloudi H, Taly A, Sola B, Jardin F. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol. 2017;10(1):47.PubMedPubMedCentralCrossRef
70.
Lee J, Jo DH, Kim JH, Cho CS, Han JE, Kim Y, et al. Development of a patient-derived xenograft model of glioblastoma via intravitreal injection in mice. Exp Mol Med. 2019;51(4):43.PubMedCentral
71.
Wang S, Han X, Wang J, Yao J, Shi Y. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS One. 2014;9(3):e89848.PubMedPubMedCentralCrossRef
72.
Sun H, Hattori N, Chien W, Sun Q, Sudo M, E-Ling GL, et al. KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer. 2014;111(2):281–91.PubMedPubMedCentralCrossRef
73.
Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, et al. Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2020;26(6):1338–48.PubMedCrossRef
74.
Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, et al. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro-Oncology. 2015;17(5):697–707.PubMedCrossRef
75.
Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016;30(1):190–9.PubMedCrossRef
76.
Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122(17):3034–44.PubMedPubMedCentralCrossRef
77.
Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015;125(20):3128–32.PubMedPubMedCentralCrossRef
78.
Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155–65.PubMedCrossRef
79.
Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013;41(1):67–78 e64.PubMedCrossRef
80.
XPO1 inhibitor approved for multiple myeloma. Cancer Discov. 2019;9(9):1150–1.
81.
Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142–50.PubMedPubMedCentralCrossRef
82.
Gounder MM, Somaiah N, Attia S, Chawla SP, Villalobos VM, Chmielowski B, et al. Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: a phase 2/3, randomized, double blind, placebo controlled cross-over study. J Clin Oncol. 2018;36(15_suppl):11512.CrossRef
83.
Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, et al. A phase II trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer. Oncologist. 2018;23(6):656–e664.PubMedPubMedCentralCrossRef
84.
Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, et al. A phase II trial of selinexor (KPT-330) for metastatic triple-negative breast cancer. Oncologist. 2019;24(7):887–e416.PubMedPubMedCentralCrossRef
85.
Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165–74.PubMedPubMedCentralCrossRef
86.
Bhatnagar B, Walker AR, Mims AS, Vasu S, Klisovic RB, Behbehani G, et al. Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia. J Clin Oncol. 2018;36(15_suppl):7048.CrossRef
87.
Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, et al. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018;11(1):4.PubMedPubMedCentralCrossRef
88.
Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, et al. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica. 2018;103(10):1642–53.PubMedPubMedCentralCrossRef
89.
Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui CH, Rubnitz JE. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J Clin Oncol. 2016;34(34):4094–101.PubMedPubMedCentralCrossRef
90.
Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129(24):3175–83.PubMedCrossRef
91.
Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2018;131(8):855–63.PubMedCrossRef
92.
Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859–66.PubMedPubMedCentralCrossRef
93.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–38.PubMedCrossRef
94.
Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546–54.PubMedPubMedCentralCrossRef
95.
Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130(9):1132–43.PubMedPubMedCentralCrossRef
96.
Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017;31(1):143–50.PubMedCrossRef
97.
Liu Y, Azizian NG, Dou Y, Pham LV, Li Y. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J Hematol Oncol. 2019;12(1):119.PubMedPubMedCentralCrossRef
98.
Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, et al. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase IIalpha to the nucleus. Clin Cancer Res. 2016;22(24):6142–52.PubMedPubMedCentralCrossRef
99.
Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, et al. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget. 2014;5(11):3444–54.PubMedPubMedCentralCrossRef
100.
Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, et al. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget. 2017;8(47):82144–55.PubMedPubMedCentralCrossRef
101.
Martin AP, Jacquemyn M, Lipecka J, Chhuon C, Aushev VN, Meunier B, et al. STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes. EMBO Rep. 2019;20(11):e48150.PubMedCrossRefPubMedCentral
102.
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84–7.PubMedCrossRef
103.
Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111(6):2349–54.PubMedPubMedCentralCrossRef
104.
Doench JG. Am I ready for CRISPR? A user’s guide to genetic screens. Nat Rev Genet. 2018;19(2):67–80.PubMedCrossRef
105.
Ventola CL. Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. P T. 2013;38(9):545–60.PubMedPubMedCentral
106.
Low SK, Takahashi A, Mushiroda T, Kubo M. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20(10):2541–52.CrossRef
Metadata
Title
XPO1-dependent nuclear export as a target for cancer therapy
Authors
Nancy G. Azizian
Yulin Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2020
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-020-00903-4

Other articles of this Issue 1/2020

Journal of Hematology & Oncology 1/2020 Go to the issue

Research

MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming

Letter to the Editor

Identification of cross-talk between m6A and 5mC regulators associated with onco-immunogenic features and prognosis across 33 cancer types

Rapid communication

PTENP1 is a ceRNA for PTEN: it’s CRISPR clear

Editorial

Anticancer drug R&D landscape in China

Review

Targeting autophagy to overcome drug resistance: further developments

Research

Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits